Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biomarkers of response and resistance to antiangiogenic therapy

Biomarkers of response and resistance to antiangiogenic therapy No validated biomarkers currently exist for appropriately selecting cancer patients for antiangiogenic therapy. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged as suitable candidate biomarkers, but all require prospective validation. The authors discuss the current challenges in establishing biomarkers, the advantages and disadvantages of systemic, circulating, tissue and imaging biomarkers, and the future opportunities for validating biomarkers of antiangiogenic therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Reviews Clinical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/biomarkers-of-response-and-resistance-to-antiangiogenic-therapy-Jr3e0K4f90

References (90)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Nature Publishing Group
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1759-4774
eISSN
1759-4782
DOI
10.1038/nrclinonc.2009.63
Publisher site
See Article on Publisher Site

Abstract

No validated biomarkers currently exist for appropriately selecting cancer patients for antiangiogenic therapy. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged as suitable candidate biomarkers, but all require prospective validation. The authors discuss the current challenges in establishing biomarkers, the advantages and disadvantages of systemic, circulating, tissue and imaging biomarkers, and the future opportunities for validating biomarkers of antiangiogenic therapy.

Journal

Nature Reviews Clinical OncologySpringer Journals

Published: Jun 1, 2009

There are no references for this article.